ARCHIVES

Aflibercept-Docetaxel Combination Misses Primary Survival Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 3 | March 25, 2011

Download PDF Visit The Full Archive

Related Articles

Cetuximab Plus Chemoradiation Boosts Survival in Phase II Study

June 24, 2011

Obituary: Michale Keeling, of M.D. Anderson.

January 2, 2004

Doxil/Caelyx Survival 3 Weeks Longer Than Topotecan

November 28, 2003

CMS also decided to cover off-label uses of approved colorectal cancer drugs in clinical trials, and allowed broader use of PET scans.

November 5, 2004

DCE Board Recompetition Concepts

July 17, 1987

Advisors Approve $50 Million NCI Effort To Attack Cancer On a Molecular Level

July 2, 1999